Playback speed
10 seconds
Practice Changing Positive Keytruda Trial : Chemo +IO had significant survival benefit for Advanced Squamous NSCLC (KEYNOTE-407)
By
Beacon Medical Interchange
FEATURING
Jack West
By
Beacon Medical Interchange
FEATURING
Jack West
254 views
October 29, 2018
Dr. Jack West reviews KEYNOTE-407, first line chemo/immunotherapy with pembrolizumab vs. chemo alone in advanced ...
read more ↘ squamous NSCLC, which demonstrated a significant survival benefit that should change practice in this setting.
↖ read less
read more ↘ squamous NSCLC, which demonstrated a significant survival benefit that should change practice in this setting.
↖ read less
Comments 0
Login to view comments.
Click here to Login
Lung